<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4970">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188551</url>
  </required_header>
  <id_info>
    <org_study_id>IRB10-00377</org_study_id>
    <nct_id>NCT01188551</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement</brief_title>
  <official_title>Pain Management Following Myringotomy and Tube Placement: Intranasal Dexmedetomidine Versus Fentanyl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to compare intranasal dexmedetomidine to intranasal fentanyl following
      anesthesia induction in patients undergoing myringotomy and placement of pressure
      equalization (PE) tubes in providing analgesia and smoothing emergence from general
      anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>FLACC Behavioral Pain Assessment Scale Scores</measure>
    <time_frame>30 mins. post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>FLACC Behavioral Pain Assessment Scale: each of the five categories (F) Face, (L) Legs, (A) Activity, (C) Cry, (C) Consolability is scored from 0-2, which results in a total score between 0 and 10.
0 = Relaxed and comfortable 1-3 = Mild discomfort 4-6 = Moderate pain 7-10 = Severe discomfort or pain or both</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery From General Anesthesia</measure>
    <time_frame>30 mins. post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>Post-anesthesia recovery score: Aldrete The Aldrete scoring system takes into account the patient's ability to move, respiration, circulation, consciousness, and oxygen saturation. A maximum of two points are awarded in each category and a score of 9 or 10 is required for discharge.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Otitis Media</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine w/ midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl w/ midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine w/o midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl w/o midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine (1 µg/kg) will be administered intranasally</description>
    <arm_group_label>dexmedetomidine w/ midazolam</arm_group_label>
    <arm_group_label>dexmedetomidine w/o midazolam</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>fentanyl (2 µg/kg) will be administered intranasally</description>
    <arm_group_label>fentanyl w/ midazolam</arm_group_label>
    <arm_group_label>fentanyl w/o midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Sedative given pre-op.</description>
    <arm_group_label>dexmedetomidine w/ midazolam</arm_group_label>
    <arm_group_label>fentanyl w/ midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  functional status as assigned by the American Society of Anesthesiology (ASA)
             classification of I or II (no or minimal co-morbid disease)

          -  patients scheduled for placement of bilateral myringotomy tubes

        Exclusion Criteria:

          -  history of allergy to either dexmedetomidine or fentanyl

          -  concomitant use of medications which may exaggerate the HR response of
             dexmedetomidine including digoxin or β-adrenergic antagonists.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007 Mar;8(2):115-31. Review.</citation>
    <PMID>17273114</PMID>
  </reference>
  <reference>
    <citation>Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007 Aug;105(2):374-80.</citation>
    <PMID>17646493</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>August 24, 2010</firstreceived_date>
  <firstreceived_results_date>June 26, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Joseph D. Tobias</investigator_full_name>
    <investigator_title>Chairman Dept. of Anesthesiology &amp; Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>myringotomy</keyword>
  <keyword>pressure equalization tubes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the outpatient ENT surgery service at Nationwide Children's Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine w/ Midazolam</title>
          <description>Midazolam given orally pre-op and dexmedetomidine given intranasally in OR.</description>
        </group>
        <group group_id="P2">
          <title>Fentanyl w/ Midazolam</title>
          <description>Midazolam given orally pre-op and fentanyl given intranasally in OR.</description>
        </group>
        <group group_id="P3">
          <title>Dexmedetomidine w/o Midazolam</title>
          <description>Dexmedetomidine given intranasally in OR without any pre-medication.</description>
        </group>
        <group group_id="P4">
          <title>Fentanyl w/o Midazolam</title>
          <description>Fentanyl given intranasally in the OR without any pre-medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pharmacy issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine w/ Midazolam</title>
          <description>Midazolam given orally pre-op and dexmedetomidine given intranasally in OR.</description>
        </group>
        <group group_id="B2">
          <title>Fentanyl w/ Midazolam</title>
          <description>Midazolam given orally pre-op and fentanyl given intranasally in OR.</description>
        </group>
        <group group_id="B3">
          <title>Dexmedetomidine w/o Midazolam</title>
          <description>Dexmedetomidine given intranasally in OR without any pre-medication.</description>
        </group>
        <group group_id="B4">
          <title>Fentanyl w/o Midazolam</title>
          <description>Fentanyl given intranasally in the OR without any pre-medication.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="25"/>
                <measurement group_id="B5" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="25"/>
                <measurement group_id="B5" value="100"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2.14" spread="1.01"/>
                <measurement group_id="B2" value="3" spread="2.02"/>
                <measurement group_id="B3" value="2.98" spread="1.87"/>
                <measurement group_id="B4" value="2.22" spread="1.16"/>
                <measurement group_id="B5" value="3" spread="1.59"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="5"/>
                <measurement group_id="B5" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="20"/>
                <measurement group_id="B5" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="25"/>
                <measurement group_id="B5" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FLACC Behavioral Pain Assessment Scale Scores</title>
        <description>FLACC Behavioral Pain Assessment Scale: each of the five categories (F) Face, (L) Legs, (A) Activity, (C) Cry, (C) Consolability is scored from 0-2, which results in a total score between 0 and 10.
0 = Relaxed and comfortable 1–3 = Mild discomfort 4–6 = Moderate pain 7–10 = Severe discomfort or pain or both</description>
        <time_frame>30 mins. post-op</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine w/ Midazolam</title>
            <description>Midazolam given orally pre-op and dexmedetomidine given intranasally in OR.</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl w/ Midazolam</title>
            <description>Midazolam given orally pre-op and fentanyl given intranasally in OR.</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine w/o Midazolam</title>
            <description>Dexmedetomidine given intranasally in OR without any pre-medication.</description>
          </group>
          <group group_id="O4">
            <title>Fentanyl w/o Midazolam</title>
            <description>Fentanyl given intranasally in the OR without any pre-medication.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>FLACC Behavioral Pain Assessment Scale Scores</title>
            <description>FLACC Behavioral Pain Assessment Scale: each of the five categories (F) Face, (L) Legs, (A) Activity, (C) Cry, (C) Consolability is scored from 0-2, which results in a total score between 0 and 10.
0 = Relaxed and comfortable 1–3 = Mild discomfort 4–6 = Moderate pain 7–10 = Severe discomfort or pain or both</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5" spread="4.19"/>
                  <measurement group_id="O2" value="3" spread="3.60"/>
                  <measurement group_id="O3" value="1" spread="2.20"/>
                  <measurement group_id="O4" value="2" spread="2.92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recovery From General Anesthesia</title>
        <description>Post-anesthesia recovery score: Aldrete The Aldrete scoring system takes into account the patient's ability to move, respiration, circulation, consciousness, and oxygen saturation. A maximum of two points are awarded in each category and a score of 9 or 10 is required for discharge.</description>
        <time_frame>30 mins. post-op</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine w/ Midazolam</title>
            <description>Midazolam given orally pre-op and dexmedetomidine given intranasally in OR.</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl w/ Midazolam</title>
            <description>Midazolam given orally pre-op and fentanyl given intranasally in OR.</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine w/o Midazolam</title>
            <description>Dexmedetomidine given intranasally in OR without any pre-medication.</description>
          </group>
          <group group_id="O4">
            <title>Fentanyl w/o Midazolam</title>
            <description>Fentanyl given intranasally in the OR without any pre-medication.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Recovery From General Anesthesia</title>
            <description>Post-anesthesia recovery score: Aldrete The Aldrete scoring system takes into account the patient's ability to move, respiration, circulation, consciousness, and oxygen saturation. A maximum of two points are awarded in each category and a score of 9 or 10 is required for discharge.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.67" spread="1.33"/>
                  <measurement group_id="O2" value="9" spread="0.96"/>
                  <measurement group_id="O3" value="9.25" spread="0.94"/>
                  <measurement group_id="O4" value="9.5" spread="0.74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine w/ Midazolam</title>
          <description>Midazolam given orally pre-op and dexmedetomidine given intranasally in OR.</description>
        </group>
        <group group_id="E2">
          <title>Fentanyl w/ Midazolam</title>
          <description>Midazolam given orally pre-op and fentanyl given intranasally in OR.</description>
        </group>
        <group group_id="E3">
          <title>Dexmedetomidine w/o Midazolam</title>
          <description>Dexmedetomidine given intranasally in OR without any pre-medication.</description>
        </group>
        <group group_id="E4">
          <title>Fentanyl w/o Midazolam</title>
          <description>Fentanyl given intranasally in the OR without any pre-medication.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph D. Tobias, MD</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>614-722-4200</phone>
      <email>Joseph.Tobias@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
